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Abstract SorLA is an established sorting and trafﬁcking
protein in neurons with demonstrated relevance to
Alzheimer’s disease (AD). It shares these roles with the
caveolins, markers of membrane rafts microdomains. To
further our knowledge on sorLA’s expression and trafﬁc,
we studied sorLA expression in various cultured glia and
its relation to caveolin-1 (cav-1), a caveolar microdomain
marker. RT-PCR and immunoblots demonstrated sorLA
expression in rat C6 glioma, primary cultures of rat
astrocytes (PCRA), and human astrocytoma 1321N1 cells.
PCRA were determined to express the highest levels of
sorLA’s message. Induction of differentiation of C6 cells
into an astrocyte-like phenotype led to a signiﬁcant
decrease in sorLA’s mRNA and protein expression. A set
of complementary experimental approaches establish that
sorLA and cav-1 directly or indirectly interact in glia: (1)
co-fractionation in light-density membrane raft fractions of
rat C6 glioma, PCRA, and human 1321N1 astrocytoma
cells; (2) a subcellular co-localization distribution pattern
in vesicular perinuclear compartments seen via confocal
imaging in C6 and PCRA; (3) additional confocal analysis
in C6 cells suggesting that the perinuclear compartments
correspond to their co-localization in early endosomes and
the trans-Golgi; and; (4) co-immunoprecipitation data
strongly supporting their direct or indirect physical inter-
action. These ﬁndings further establish that sorLA is
expressed in glia and that it shares its subcellular distri-
bution pattern with cav-1. A direct or indirect cav-1/sorLA
interaction could modify the trafﬁcking and sorting func-
tions of sorLA in glia and its proposed neuroprotective role
in AD.
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Introduction
Glia exerts physiological (Hansson and Ro ¨nnba ¨ck 2003)
and pathophysiological functions during brain injury,
tumorigenesis, aging, and neurodegeneration (Eddleston
and Mucke 1993; Ridet et al. 1997). During these events,
glia may exert opposite ‘‘cytoprotective versus cytotoxic’’
actions, depending on the type of insult, its character,
extent, and time point (Eddleston and Mucke 1993; Ridet
et al. 1997; Mattson and Chan 2003; Fellin and Carmignoto
2004; Chorna et al. 2004; Sofroniew and Vinters 2010). In
Alzheimer’s disease (AD), neurodegeneration astrocytes
(Mattson and Chan 2003; Selkoe 2004; Mrak and Grifﬁn
2005) surround senile plaques, inﬁltrate plaque cores (Kato
et al. 1998), produce the pro-neurotoxin amyloid precursor
protein (APP) (Nagele et al. 2004), and synthesize–secrete
the established risk factor apolipoprotein E (ApoE) (Poirier
1994).
A novel receptor for APP and ApoE, the sortilin-related
receptor sorLA (LR11 or sorL1), implicated in smooth
muscle cell proliferation and invasion (Kanaki et al. 1999),
has emerged as an important factor in AD pathogenesis
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DOI 10.1007/s10571-011-9771-5(Yamazaki et al. 1996; Jacobsen et al. 2002; Motoi et al.
1999; Herz et al. 2009). To date, few studies on sorLA have
focused on glia (Motoi et al. 1999; Scherzer et al. 2004;
Macdonald et al. 2007). SorLA is a multifunctional, mul-
tidomain 250 kDa membrane protein related to LDL
receptors’ family (Yamazaki et al. 1996; Jacobsen et al.
2002; Herz et al. 2009). A downregulation of sorLA in
lymphoblast and brains of AD patients (Scherzer et al.
2004; Offe et al. 2006) has been associated as a sporadic
AD risk factor (Andersen et al. 2005) and a late onset
Alzheimer disease (LOAD) marker (Rogaeva et al. 2007;
Bettens et al. 2008). Also sorLA has been identiﬁed as a
predictor in progression to AD in mild cognitive impair-
ment (MCI) patients (Sager et al. 2007). Single nucleotide
polymorphisms and haplotypes in sorLA are also found in
diverse ethnicity AD patients (Lee et al. 2007; Rogaeva
et al. 2007, 2009;K o ¨lsch et al. 2009).
Understanding sorLA’s role in AD (Huse and Doms
2001; Reid et al. 2007) demands expansion of its studies in
glia, and in the importantly emerging membrane raft
microdomains (Silva et al. 2007). SorLA functions as a
sorting and trafﬁcking protein, preventing formation of
amyloidogenic peptides from APP (Offe et al. 2006;
Schmidt et al. 2007). Although sorLA moves to the plas-
malemma and internalizes via clathrin-dependent endocy-
tosis (Andersen et al. 2005; Nielsen et al. 2007), membrane
raft microdomains and raft-associated molecules like the
caveolins (Pike 2006; Silva et al. 2007) may participate in
this trafﬁcking. Membrane rafts are small (10–200 nm),
heterogeneous, highly dynamic, cholesterol- and sphingo-
lipid-enriched domains that compartmentalize cellular
processes related to trafﬁcking, signaling, protein sorting,
and targeting (Pike 2006). Indeed, membrane raft proteins
as caveolins and ﬂotillins have been associated with APP
and with different APP processing stages (Ikezu et al.
1998; Nishiyama et al. 1999; Kang et al. 2006; Rajendran
and Simons 2009; Reid et al. 2007; Schneider et al. 2008;
Silva et al. 2007).
Cav-1 physically associates with APP in three non-
neuronal cell lines, while a-secretase-mediated proteolysis
of APP was shown to occur in CAV (caveolae microdo-
mains (Ikezu et al. 1998). In addition, the cav-1 protein is
up-regulated in the hippocampus (and its mRNA in the
frontal cortex) of AD patients, and in hippocampal tissue
from ApoE-knockout and aged wild-type mice, and the
frontal cortex of AD patients (Gaudreault et al. 2004a).
Up-regulation of cav-1 is also seen in senescent human
brain, and senescent rat brain membrane raft fractions
(Kang et al. 2006). The above cited concomitant changes in
both cav-1 and sorLA expressions during AD may be inti-
mately linked to glia. To date, no studies have evaluated in
parallel the expression of sorLA in glia, its membrane rafts
platform, and glial raft-associated molecules like cav-1.
Therefore, it is hypothesized that sorLA in glia shares its
subcellular distribution proﬁle with cav-1. The present
study demonstrates that sorLA in glia co-compartmentalizes
with cav-1, predominantly in intracellular sites suggesting a
direct or indirect interaction that may constitute a novel
target for the modulation of AD progression.
Materials and Methods
Cell Cultures
C6 glioma cells (Cell Systems, Seattle, WA) grown in
Nutrient Mixture Ham’s F-10 media containing 10% FBS
and 1% antibiotic/antimycotic were routinely propagated
as conﬂuent monolayers (Silva et al. 2005). 1321N1
(human astrocytoma), primary cultures of rat astrocytes
(PCRA), and primary cultures of rat neurons (PCRN)
(obtained from the NIH-NCRR-RCMI-supported Neuronal
Glia Culture Facility of Universidad Central del Caribe
School of Medicine, Bayamo ´n, PR) were grown in Dul-
becco’s Modiﬁed Eagle media containing 10% fetal bovine
serum (FBS) and 1% antibiotic/antimycotic. The cells were
routinely propagated as conﬂuent monolayers. Induction of
C6 glial cells differentiation into astrocyte-like cells was
achieved by the addition of 1 mM dibutyryl cyclic AMP
(db-cAMP) and reduction of growth media to 1% FBS
(Silva et al. 2005). Cells were seeded on cover slips of
dual-chamber slides at *1 9 10
4 cells/well for immuno-
ﬂuorescences or in plates at *1 9 10
6 cells/well for
mRNA and protein extraction. The cells were incubated at
37C, in 5% CO2.
Real Time RT-PCR
Determination of sorLA expression was done via real time
RT-PCR. Primers were designed using Bio-Rad’s Beacon
Designer 5 software (Bio-Rad Laboratories, Hercules, CA)
and the following mRNA sequences: rat sorLA (accession
number XM217115), human sorLA (accession number
NM003105),andratGAPDH(accessionnumberAF106860).
The following PCR primers were used for the detection of
sorLA and GAPDH transcripts: rat sorLA sense primer
50-TGTGTAAGAACCGTCAGCAGTGTC-30 and antisense
primer50-AGTAGTCTCCGCAGTCATCCATCC-30 (216 bp);
human sorLA sense primer 50-TCAGTGGAGACAACA
GTAAGG-30 and antisense primer 50 AGGAGGTGGACA
GACAGG-30 (318 bp); and, rat GAPDH sense primer
50-AACTTTGGCATCGTGGAA-30 and antisense 50-TACA
TTGGGGGTAGGAACAC-30 (222 bp). Real time RT-PCR
was performed in an iCycler using the iQ SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, CA). After opti-
mization of PCR conditions, reactions were conducted with
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primersand100 ngofcDNA.PCRparameterswere95Cfor
3 min (required for iTaq DNA polymerase activation),
40 cycles of 95C for 10 s, and 1 min annealing at 55C for
ratandhumansorLAprimers.ThegenerationofspeciﬁcPCR
products was conﬁrmed by melt curves and separation of the
productsoveragarosegels.PCRcyclenumberthatgenerated
theﬁrstﬂuorescencesignalabovethreshold(thresholdcycle,
CT) was determined, and subsequently, a comparative CT
method (Livak and Schmittgen 2001) using GAPDH for
normalization was used to measure relative gene expression
as previously described (Silva et al. 2005). Mean values of
datafromthreeindependentexperimentswerecalculatedand
plotted as a percentage compared with undifferentiated C6
controls (which were set to 100%). RT-PCR analysis was
conducted using the NIH-NIGMS-MBRS-SCORE-sup-
ported Molecular Core Facility of the UPR-MSC.
Protein Extraction
Conﬂuent C6 glioma cells culture dishes were placed on
ice and washed twice with ice-cold PBS. After PBS was
removed, 1 ml was added of ice-cold cell lysis buffer (LB)
[NaCl 150 mM, Tris HCl 50 mM pH 8.0, octyl-glucoside
60 mM, EDTA 5 mM, PMSF 0.2 mM, and a protease
inhibitors cocktail (100 lg/ml each of leupeptin, antipain,
bestatin, chymostatin, and pepstatin A)]. Adherent cells
were scrapped off from the culture dish using a cold plastic
scrapper. Cells were then centrifuged in a cold microcen-
trifuge for 20 min at 12,000 rpm. The resulting supernatant
was transferred into a new microtube and placed on ice for
total protein determination, following the Bio-Rad Protein
assay protocol (Bio-Rad Laboratories, Hercules, CA).
Preparation of Caveolin-1-Enriched Membrane Rafts
Fractions
Density gradient fractionation procedures under detergent-
free conditions were performed as previously described
(Silva et al. 1999). Lysis buffer containing 500 mM sodium
bicarbonate and a cocktail of protease inhibitors (that
included PMSF, antipain, bestatin, leupeptin, chemostatin,
pepstatin, and EDTA) was added, the cells were scraped,
and then homogenized. Discontinuous gradients were pre-
pared by adjusting the homogenate to 45% sucrose by the
addition of 90% sucrose in MBS, overlaying with 4 ml of
35% sucrose in MBS, and 4 ml 5% sucrose in MBS.
Samples were centrifuged at 100,0009g for 22 h in a SW
40Ti rotor (Beckman Instruments). Gradient fractions (12)
were collected (1 ml), washed with MBS, centrifuged at
100,0009g for 30 min, the resulting pellets resuspended in
urea sample buffer (USB) (4% SDS, 8 M urea, 62 mM
EDTA, 5% mercaptoethanol, and 0.015% bromophenol
blue), boiled, and equal sample volumes were loaded into
SDS-PAGE gels.
Immunoprecipitation
Conﬂuent C6 glioma cells culture dishes were placed on ice
and washed twice with ice-cold PBS. After PBS was
removed, 1 ml was added of ice-cold LB and a protease
inhibitors cocktail (100 lg/ml each of leupeptin, antipain,
bestatin, chymostatin, and pepstatin A). Adherent cells were
scrapped and the cell suspension transferred to a pre-cooled
microcentrifuge tube and incubated in rocking motion at
4C for 30 min. The suspension was then centrifuged at 4C
for 20 min at 12,000 rpm. The resulting supernatant was
transferred into a new microtube and placed on ice for total
protein determination. Next, we combined 0.5 mg of the
cell suspension and 1 lg of antibody (anti-sorLA or anti-
cav-1), and the total volume was made up to a ﬁnal volume
of 1 ml using ice-cold LB. Samples were incubated over-
night at 4C, and then 40 ll of protein A/G beads (Thermo
Scientiﬁc, Rockford, IL) was added and incubated at 4C
for 2 h. Samples were precipitated at 4C for 15 s at
12,000 rpm, and the resultant supernatant discarded. The
immunocomplex was washed three times with ice-cold
immunoprecipitation buffer [NaCl 150 mM, Tris HCl
50 mM pH 8.0, octyl-glucoside 60 mM, and EDTA 5 mM),
and then twice with ice-cold TBS (NaCl 150 mM, Tris HCl
50 mM pH 8.0). The resultant immunocomplex was sus-
pended in Laemmli sample buffer (Bio-Rad Labs, Hercules,
CA). The samples were separated in a SDS-PAGE and
immunoblotted as described below.
Western Blots
For SDS-PAGE and immunoblotting, equal sample vol-
umes from cell protein extracts, gradient fractions, and
immunoprecipitates were separated in 6% or 10% SDS
polyacrylamide gels, and transferred to PVDF membranes
with a Bio-Rad Semi-Dry (Bio-Rad Laboratories, Hercules,
CA) (Silva et al. 2005). Membranes were blocked with
3–5% non-fat milk, incubated overnight with primary
polyclonal antibody against cav-1 (1:5,000) (Sigma-
Aldrich, St. Louis, MO), a monoclonal antibody against
ﬂotillin-2 (ﬂot-2) (1:250), a monoclonal antibody for sor-
LA/LR11 (1:250) (BD Biosciences, San Jose, CA). Sub-
sequently, secondary antibodies: anti-rabbit polyclonal
(1:10,000) or anti-mouse monoclonal (1:10,000) (Sigma-
Aldrich, St. Louis, MO) were added for 1 h at room tem-
perature (RT). Blots were developed using the enhanced
chemiluminescence kit SuperSignal
 (Pierce, Rockford,
IL), and images obtained using a Bio-Rad Gel Doc 1000
system (Bio-Rad Laboratories, Hercules, CA) (NIH-NIG-
MS-MBRS-SCORE Molecular Core Facility, UPR-MSC).
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For immunoﬂuorescence studies, culture media were dec-
anted, cells rinsed with PBS, ﬁxed with 100% methanol
(-20C), rinsed with PBS and treated with 100 mM NH4Cl
in PBS to quench free aldehyde groups. Cells were rinsed,
permeabilizedwith0.1%TritonX-100,andincubatedin2%
BSA in PBS to reduce non-speciﬁc antibody binding for
30 min. Incubation with primary antibodies against sorLA,
early endosome antigen-1 (EEA-1) (BD Biosciences, San
Jose,CA),transGolginetwork(TGN-38),andcav-1(Sigma-
Aldrich, St. Louis, MO), and with Alexa-coupled secondary
antibodies (Invitrogen, Grand Island, NJ) was done for 1 h
each at RT. Slides were washed and mounted with anti-
fading medium Slowfade
 Antifade Kit (Molecular Probes,
Eugene, OR). Laser scanning confocal microscopy (LSCM)
studies were done with excitation using a 488-nm Argon/2
laser and/or 633 He/Ne laser, and emission acquired using a
BP 500-550 or a LP 650 ﬁlter on a Zeiss LSM510 Confocal
Microscope.Imageswereobtained,andanalysiswasdoneat
the NIH-NCRR-RCMI- and NSF-EPSCOR-supported
Confocal Imaging Facility at the University of Puerto Rico,
Rı ´o Piedras Campus, Rı ´o Piedras, PR.
Co-localization Analysis
The three-dimensional co-localization analysis was carried
out using the Imaris X.64 6.2.0 software (Bitplane AG,
Zurich Switzerland). This software implements an algo-
rithm developed by Costes et al. (2004) based on a spatial
statistical approach, which automatically and reproducibly
quantiﬁes co-localization, thus eliminating visual bias upon
the analysis. Imaris x.64 6.2.0 tests for true co-localization
by applying a randomization step before co-localization
quantiﬁcation. The test consists in determining if the
probability (P-value) that the Pearson’s correlation coefﬁ-
cient (r) (Manders et al. 1992) calculated for the two
channels is signiﬁcantly greater than that calculated if only
random overlap was present. A P-value greater than 95%
has been chosen as indicative of true co-localization. The
thresholds were automatically calculated by iteratively
calculating r while decreasing thresholds until r are equaled
to zero (Costes et al. 2004). Collected z-stacks were
background-subtracted by determining the mean intensity
of ﬂuorescence outside cells and subtracting this intensity
value to the collection of voxels in the image. Costes
algorithm (Costes et al. 2004) requires that a region of
interest be selected before the automatic calculation of
thresholds to delimited the boundary of the cells were
selected. Upon automatic calculation of thresholds,
‘‘co-localization channels’’ were generated which highlight
co-localized voxels in white and can be combined with the
two channels under study to create a merged image.
Statistical Analysis
Mean values of data from at least three independent
experiments were subsequently calculated and plotted as a
percentage compared with untreated controls (which were
set to 100%). Standard errors were calculated by one-way
analysis of variance (ANOVA) and by Students’ paired
t test. The signiﬁcance between groups was further ana-
lyzed using the post-hoc Tukey test using Graph Pad Prism
software (Graph Pad Software Inc., San Diego, CA).
Results
Determination of SorLA Expression in a Series of Glial
Cell Model Systems
Studies on sorLA have primarily focused on neuronal cells.
In the present study, evaluation of sorLA mRNA expres-
sion was done in a series of glial cell model systems (rat C6
glioma, PCRA and human 1321N1 astrocytoma cells), and
in parallel in the human SH-SY5Y neuroblastoma cell line
and PCRN. Our results demonstrate that the different
human/rat and malignant/non-malignant glial cell model
systems, as well as the control human neuroblastoma cell
line SH-SY5Y and PCRN, express sorLA’s message
(Fig. 1a). Ampliﬁcation curves obtained using speciﬁc
primers for human and rat sorLA revealed the expression
of a primary single reaction product in all glial cells tested
(Fig. 1b). In addition, separation of the reaction products
using agarose gel electrophoresis revealed products of the
corresponding expected sizes for human sorLA (318 bp)
and rat sorLA (216 bp) (Fig. 1b). Comparison of the rela-
tive levels of transcript expression in the rat cell cultures
(Fig. 1c) revealed that PCRA express the highest levels of
mRNA when compared to the two C6 cells and PCRN
(N = 3, ***P B 0.001). No signiﬁcant difference in tran-
script expression was found between the human SHSY-5Y
neuroblastoma and the human 1321N1 astrocytoma cells.
SorLA’s Downregulation During Differentiation of C6
Glioma Cells
Differentiation of the rat C6 glioma cell line using low
serum and 1 mM db-cAMP into an astrocyte-like pheno-
type, as revealed by an increased GFAP expression (Silva
et al. 2005) resulted in a signiﬁcant (N = 3, ***P B 0.001)
downregulation (*75%) in sorLA’s transcript expression
after 8-, 24-, and 48-h post-induction of differentiation
(Fig. 2). Densitometry analysis of the *250 kDa sorLA
band (Fig. 3b) obtained via immunoblots also demon-
strated a signiﬁcant downregulation of the sorLA’s protein
in the differentiated phenotype (T48) when compared to
Cell Mol Neurobiol
123undifferentiated (T0) cells (decrease of 46.1% ± 11.69%;
P B 0.01) (Fig. 3c). The India ink staining (Fig. 3a) was
used for total protein content estimates and correction.
SorLA Co-Fractionates with Membrane Rafts Proteins
(Cav-1 and Flot-2) Using Density Gradient
Centrifugation Under Detergent-Free Conditions
Sucrose density gradient centrifugation under detergent-
free conditions was performed to further provide evidence
on the expression of sorLA in glial cells, and establish if it
co-fractionates with the membrane raft protein cav-1
(Fig. 4). The results corroborate sorLA protein expression
in the two C6 phenotypes, and establish its expression in
PCRA and 1321N1 astrocytoma cells (fractions 4–5 in
Fig. 4a–d). In addition, Fig. 4a–d shows that sorLA also
co-fractionates with the membrane raft marker protein ﬂot-
2 in light-density membrane raft fractions (fractions 4–5)
obtained under detergent-free conditions, in all of the
cultured glia tested.
Immunocytochemical Analysis of SorLA Expression
in Glia and its Co-Localization with Cav-1
To further the characterization of sorLA in glia, we per-
formed immunoﬂuorescence confocal co-localization
analysis in undifferentiated (T0) cells C6 (Fig. 5, top
panel), differentiated C6 (T48) (Fig. 5, middle panel), and
Fig. 1 SorLA’s mRNA
expression in glia and neuron
cells. a the real time RT-PCR
melt curves for human and rat
cells model systems.
b representative gels conﬁrming
the expected size of the
ampliﬁed sorLA sequence in rat
and human cells. c the relative
expression levels of sorLA in
rat cells and human cells,
demonstrating a major
expression of sorLA in PCRA
and similar levels of sorLA in
the primary cultures of rat
neurons (PCRN) cells, C6 glial
cells and human cells (SHSY-
5Y and 1321N1 astrocytoma
cells). Each bar represents the
mean ± SEM of at least three
experiments (N = 3,
***P B 0.001)
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123PCRA (Fig. 5, bottom panel). As can be seen, sorLA
(green staining) displays a subcellular distribution pattern
similar to the one detected in neurons and other cell types
(Andersen et al. 2005; Nielsen et al. 2007; Bujo and Saito
2000). In all cases, the immunostaining pattern of sorLA is
characterized by a diffuse dotted-punctuate labeling of
cytoplasmic vesicles and plasmalemma, with a prominent
labeling of larger intracellular vesicular structures. The
intracellular and perinuclear labeling exhibited by sorLA
has been shown to correspond to its transit via the clathrin-
mediated endocytic path to EE and its shuttling to-and-
from the trans-Golgi (Offe et al. 2006), assisted by its
vps10p domain (Marcusson et al. 1994; Yamazaki et al.
1996; Jacobsen et al. 2002). The cav-1 immunostaining
(red) exhibits a subcellular distribution pattern character-
ized by intensely ﬂuorescent punctae throughout the cyto-
plasm and diffuse micropatches at the level of the
plasmalemma. In all cells analyzed (Fig. 5) a very discrete
co-localization was also seen at the level of the plasma-
lemma (see inserts boxes for each cell type), a region de-
marked in the sections shown by the presence of the CAV
micropatches in C6 (Silva et al. 1999, 2005). Plasmalemma
level co-localization pixels were more evident in differ-
entiated C6 cells (Fig. 5, middle panel).
Fig. 2 SorLA’s mRNA downregulation in C6 glial cells differenti-
ation and demonstrates that differentiation of C6 cells into an
astrocyte-like phenotype results in a signiﬁcant downregulation of
sorLA’s mRNA expression after 8, 24 and 48 h post-differentiation
induction. Each bar represents the mean ± SEM (N = 4, **P B 0.01)
Fig. 3 Western blot analysis of sorLA’s expression in undifferenti-
ated (To, control) and differentiated (T48, 48-h post db-cAMP-
induced differentiation) C6 glioma cells. a represents the India Ink
staining of the membrane used to determine the relative protein
content. b the membranes for the analysis of the 250-kDa band
corresponding to the sorLA’s expression using 50 lg of protein from
total homogenate of C6 glioma cells at undifferentiated and
differentiated states induced with db-cAMP along with molecular
weight makers (M). Equal amounts of samples were loaded and
separated by SDS-PAGE. c demonstrates the densitometry analysis
for sorLA. Optical density for the speciﬁc bands was performed and
corrected by protein content. Results represent a 46.1% of change in
differentiated phenotype relative to the undifferentiated cells. Each
bar represents the mean ± SEM of at least four experiments (N = 4,
**P B 0.01)
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ment(s) involved in the observed sorLA and cav-1
co-localization, a LSCM analysis was done in undifferen-
tiated C6 using EEA-1 as a marker for the early endosomal
(EE) compartment or TGN-38 for the trans-Golgi (TGN)
network. Figure 6a (top) reveals intracellular co-localiza-
tion between sorLA (green) and EEA-1 (red) in the larger
intracellular vesicular structures corresponding to the EE
compartment, a result consistent with those reported for
sorLA in neurons (Andersen et al. 2005). Similarly,
co-localization was also observed between cav-1 (green)
and EEA-1 (red) in the larger intracellular vesicular
structures corresponding to the EE compartment (Fig. 6a,
bottom), as has previously been shown in other cell types.
The EE compartment is an intracellular site where both
molecules converge. Convergence of sorLA and cav-1 in
the TGN is also inferred form the parallel co-localization
analysis done using TGN-38 as a marker (Fig. 6b). In this
case, the classical perinuclear staining for TGN (Fig. 6b)
was observed, and co-localization observed for both sorLA
(green) and TGN-38 (red) (Fig. 6b, top), as well as
between cav-1 (green) and TGN-38 (red) (Fig. 6b, bottom).
Co-localization dots (white panel) and merged (green/red)
images in Fig. 6 clearly demonstrate these shared
co-localization patterns.
SorLA and Cav-1 Directly or Indirectly Interact
as Determined by Immunoprecipitation Analysis
Immunoprecipitation analysis was performed to further
provide evidence of a physical (direct or indirect) inter-
action between sorLA and cav-1 in undifferentiated C6
glioma cells. Figure 7 (left panel) reveals that cav-1
immunoreactivity is detected in immunoprecipitation
complexes obtained by the use of beads coupled to either
anti-sorLA or anti-cav-1 (positive control) antibodies.
While sorLA immunoreactivity (right panel) is also
detected in immunoprecipitation complexes obtained using
either anti-sorLA (positive control) or anti-cav-1 coupled
beads. As a negative control Western blots against cav-1
were done on membranes from immunoprecipitates
obtained with beads only (left panel). This immunopre-
cipitation analysis is consistent with sorLA’s co-fraction-
ation in cav-1-positive light-density membrane raft
Fig. 4 Membrane rafts
subfractionation via sucrose
density gradients and detergent-
free conditions. Immunoblotting
representing the co-
fractionation of sorLA with a
expected band of *250 kDa,
and the membrane raft markers
ﬂotillin-2 and cav-1 with a
molecular weight of *48 and
*22 kDa, respectively are
shown for undifferentiated
(a) and differentiated (b)C 6
glioma, the human astrocytoma
cell line 13121N1 (c) and PCRA
(d). Twelve 1-ml fractions were
collected from the top (left side)
to the bottom (right side). The
light-density, membrane raft
fractions (fractions 4–5) and
caveolin-enriched are deﬁned
by intense cav1 and ﬂotillin-2
labeling
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(Fig. 4), and their patterns of co-localization obtained via
confocal imaging analysis (Figs. 5, 6).
Discussion
Few studies have analyzed in depth sorLA in glia. An
initial study in brain tissue (Motoi et al. 1999) did not
detect sorLA labeling in glia, while Scherzer et al. (2004)
described no-changes in sorLA immunostaining in glia of
AD patients. A third study in the literature reported
downregulation of sorLA using microarrays gene analysis
of human astrocytoma brains (Macdonald et al. 2007). The
present study expands characterization of sorLA expression
to a series of normal and transformed human and rat glia.
The results presented provide evidence of its message
expression in C6, PCRA, and 1321N1 astrocytoma
(Fig. 1a, b). Among the latter cell lines, PCRA displays the
highest levels of sorLA mRNA expression when compared
to the two C6 cells (Fig. 1c). A possible explanation for
the apparent discrepancy between the downregulation of
sorLA expression during rat glioma differentiation and the
highest levels of expression observed in primary rat
astrocyte respect to tumoral cells could be associated to the
differential production of neurotrophic factors between
these cell types. C6 glioma cells are reactive astrocyte-like,
but these are still transformed cells that can behave dif-
ferent to the non-tumor astrocytic phenotype observed in
the embryonic PCRA. For instance, it has been shown that
Fig. 5 Immunoﬂuorescence analysis of sorLA and cav-1 in undif-
ferentiated C6 glioma cells (top panel), differentiated C6 cells
(middle panel), and PCRA (bottom panel). In all panels, from left to
right, we can appreciate sorLA (green) and cav-1 (red) immuno-
staining, the co-localized pixels channel (white) and the green/red
ﬂuorescence merged images. Co-localized pixels, highlighted in white
and determined using the Imaris x64 6.2.0 software, reveal sorLA and
cav-1 co-localization primarily at large intravesicular structures, with
diffuse labeling of plasmalemma and cytoplasmic punctae. At the
right hand of each panel, zoom images of large intracellular vesicular
structures and plasmalemma level immunostaining are shown. Notice
prominent sorLA labeling of intracellular vesicular structures consis-
tent with its labeling of endosomes and Golgi structures. Discrete
co-localization is seen at the plasmalemma level, being more evident
in differentiated C6 cells. Major ticks in images are separated by
5 lm. Scale bars in blue inserts: 0.6 lm (undifferentiated C6),
1.5 lm (differentiated C6), and 0.8 lm (PCRA). Scale bars in purple
inserts: 1 lm (undifferentiated C6), 1.5 lm (differentiated C6), and
1.5 lm (PCRA)
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documented elevated production of neurotrophic factor,
such as the brain-derived neurotrophic factor (BDNF)
(Lackland and Dreyfuss 2002). BDNF has been implicated
in the upregulation of sorLA’s expression (Rohe et al.
2009), since sorLA (-/-) mice treated with this neuro-
tropic factor exhibited an increase of sorLA’s transcript
accompanying by a decrease of aß peptide formation.
No signiﬁcant difference in transcript expression was
found between the human SHSY-5Y neuroblastoma and
1321N1 astrocytoma cells. Hence, relatively higher levels
of sorLA’s transcript expression in PCRA, when compared
to PCRN, support the need to further our characterization
of its expression in this brain compartment. This scenario
may be reminiscent to the enhanced expression of AD
associated molecules in the glia compartment, i.e., APOE
(Beffert et al. 2004; Poirier 2005) and speciﬁc APP iso-
forms (Gaul et al. 1992), hence underscoring the need to
unravel their signiﬁcance and contribution to the onset-
progression of the disease.
The expression of the 250 kDa sorLA was also dem-
onstrated by immunoblot analysis of total cell homogenates
(Fig. 3) and light-density membrane raft fractions from C6
(differentiated and undifferentiated), PCRA, and 1321N1
cells (Fig. 4). In the case of C6, a signiﬁcant decrease in
sorLA’s mRNA (Fig. 2) and protein (Fig. 3) expression is
Fig. 6 Immunoﬂuorescence co-localization analysis of sorLA and
cav-1 with markers of the early endosome (EE) (EEA1) and the trans-
Golgi network (TGN38) in undifferentiated C6 glioma cells. The
images in a, from left to right, we can appreciate sorLA (green) and
EEA-1 (red) immunostaining, the co-localized pixels channel (white)
and the green/red ﬂuorescence merged images. Co-localized pixels,
highlighted in white and determined using the Imaris x64 6.2.0
software, reveal sorLA and EEA-1 co-localization in the EE
compartment. Similar co-localization patterns were shown for cav-1
(green) and EEA-1 (red) immunostaining. The cav-1:EEA-1
co-localization can be appreciated in the co-localized pixels channel
(white) and the green/red ﬂuorescence merged images. Hence, both
sorLA and cav-1 co-localize in the EE compartment. In the images in
b, from left to right, we can appreciate sorLA (green) and TGN38
(red) immunostaining, the co-localized pixels channel (white) and the
green/red ﬂuorescence merged images. Co-localized pixels, high-
lighted in white and determined using the Imaris 964 6.2.0 software,
reveal sorLA and TGN38 co-localization in the TGN compartment.
Similar co-localization patterns were shown for cav-1 (green) and
TGN38 (red) immunostaining. The cav-1:TGN38 co-localization can
be appreciated in the co-localized pixels channel (white) and the
green/red ﬂuorescence merged images. Hence, both sorLA and cav-1
can also co-localize in the TGN compartment
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phenotype. Hence, C6 differentiation permits in vitro
assessment of sorLA’s downregulation. Interestingly,
immunoblots analysis revealed decreased sorLA expres-
sion in lymphoblast’s and frontal cortex from patients with
AD (Scherzer et al. 2004), and in patient subgroups with
MCI (Sager et al. 2007). Although sorLA staining in glial
cells seemed not to decrease, as found in the study of
Scherzer et al. (2004), the relative contribution of glia in
total homogenates from brain to the observed decrease
cannot be determined, nor the regional variations in glial
cell-speciﬁc protein expression estimated.
SorLA’s downregulation, coupled to up-regulation of
other factors, may generate an environment permissive of
neurotoxic amyloid peptides synthesis or an increased
amyloidogenic potential, both in neurons and glia. Inter-
estingly, there is an up-regulation of cav-1 in senescent
mouse and human brain (Gaudreault et al. 2004a; Kang
et al. 2006); in the brain of AD patients and hippocampus
of ApoE-deﬁcient mice (Gaudreault et al. 2004a); also
there is an increase in cav-1-enriched membrane raft
fractions in senescent rat brain (Kang et al. 2006). Inter-
estingly, we have previously reported cav-1 up-regulation
during C6 cells differentiation (Silva et al. 2005), which
coupled to the sorLA downregulation reported in this
study, supports an increased cav-1:sorLA ratio attained
during the differentiation process. Therefore, an increased
cav-1:sorLA ratio may correlate with neurotoxic amyloid
peptides synthesis. Indeed, in three distinct non-neuronal
cell lines, the a-secretase-mediated proteolysis of APP was
enhanced by recombinant over-expression of cav-1 and
abrogated by cav-1-based antisense oligonucleotides (Ikezu
et al. 1998). C6 cells, which are also known to express and
process APP (Morato and Mayor 1993), may hence be used
as a bioassay to study factors that can halt sorLA’s ‘‘det-
rimental’’ downregulation, increase its expression, or
modulate the cav-1:sorLA ratio. In this context, a most
critical determinant in the neurotoxic trafﬁcking (Huse and
Doms 2001) of APP in AD may be the elevated cav-1:
sorLA ratio.
Glia are thus highly relevant to our complete under-
standing of sorLA in AD, and permit further dissection of
its trafﬁcking by analysis of the membrane raft microdo-
mains and association with raft-associated proteins like
cav-1. This study demonstrates that sorLA displays buoy-
ant-density properties typical of molecules associated with
membrane rafts, since it co-fractionates with cav-1 and ﬂot-
2 in light-density membrane rafts fractions obtained from
three different glial cell model systems (Fig. 4). This
buoyant-density property of raft-associated proteins is also
exhibited by APP, which co-fractionates and co-localizes
with cav-1 in rat brain tissue (Kang et al. 2006), and with
caveolin-3 in CRT astrocytoma membrane raft fractions
(Nishiyama et al. 1999). In the case of differentiated C6
cells, it is possible that cell differentiation causes a
migration of cav-1 to heavier subcellular fractions, such as
high-density raft or non-raft plasmalemma microdomains,
or its internalization to caveosomes (Melgren 2008). The
caveosomes are higher-density cav-1-positive subcellular
fractions dispersed throughout the plasma membrane and
intracellular structures with irregular shapes, sizes, and a
non-acidic pH (Nichols 2003). This observation is
Fig. 7 Co-immunoprecipitation analysis demonstrates a direct or
indirect physical interaction between sorLA and cav-1. Left panel
displays immunoblots of membranes with an anti-cav-1 antibody,
while the right panel represents membranes probed with an anti-
sorLA antibody. The left panel shows in the ﬁrst three strips the
expected *22 kDa band corresponding to cav-1 in total cell
homogenates of undifferentiated C6 cells, and immunoprecipitates
obtained using beads coupled to a cav-1 (positive control) and sorLA.
The fourth strip in the left panel represents a negative control done
with uncoupled beads only. The right panel shows the expected
*250 kDa band corresponding to sorLA in total cell homogenates of
undifferentiated C6 cells, and immunoprecipitates obtained using
beads coupled to a sorLA (positive control) and cav-1 antibody. The
ﬁgure illustrates representative immunoblotblot analysis of PVDF
membranes from at least four experiments in each panel
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positive structures.
In addition to demonstrating sorLA (mRNA and protein)
expression in a series of glia and its co-fractionation with
raft-associated proteins, this study demonstrates in two C6
phenotypes and PCRA (Fig. 5) that sorLA displays a
subcellular distribution pattern similar to the one observed
in neurons and other cell types (Motoi et al. 1999;
Andersen et al. 2005; Nielsen et al. 2007). The immuno-
staining pattern is characterized by a diffuse dotted-punc-
tuate labeling of cytoplasmic vesicles and the
plasmalemma, with prominent labeling of larger intrave-
sicular structures. Even more, LSCM also revealed that in
both C6 phenotypes and PCRA sorLA is primarily found
co-localized with cav-1 in larger intracellular vesicular
compartments, and in diffusely distributed cytoplasmic
vesicles (Fig. 5). Also, in all cases, discrete co-localization
was seen at the plasmalemma, a region demarked in the
sections shown by the presence of the CAV micropatches
in C6 (Silva et al. 1999, 2005) (Fig. 5). Interestingly,
plasmalemma level co-localization seemed more evident in
differentiated C6 cells (Fig. 5b). This latter pattern is
consistent with studies demonstrating the ability of sorLA
to trafﬁc from the trans-Golgi to plasmalemma, internalize,
and be primarily found in intracellular endosomal and
trans-Golgi compartments (Offe et al. 2006). Similarly,
cav-1 has been found in the trans-Golgi region and in cav-
1-containing endosomes (termed caveosomes) (Parton
2004; Pol et al. 1999; Pelkmans et al. 2001, 2004; Nichols
2003; Peters et al. 2003).
The present study further demonstrates that indeed, both
sorLA and cav-1 co-localize with speciﬁc markers of the
trans-Golgi network (TGN38) and early endosomes
(EEA1) (Fig. 6). These ﬁndings strongly support the exis-
tence of a direct and/or indirect interaction between cav-1
and sorLA in their trafﬁcking and functional fates. The
indirect or direct cav-1:sorLA partnership was further
demonstrated by the mutual co-immunoprecipitation of
cav-1:sorLA complexes form C6 cells (Fig. 7). This
interaction(s) may lead to sharing and potential modulation
of their trafﬁcking and functional roles in pathways, such
as the APP amyloidogenic path.
In this context, it remains to be determined if cav-1 is
part of or interacts with the retromer complex to modulate
sorLA’s ability to sort APP (Marcusson et al. 1994;
Yamazaki et al. 1996; Jacobsen et al. 2002) away from
b- and c-secretases (Cam and Bu 2006) in late endosomal
compartments (Seaman 2004; He et al. 2005) leading to
decreased Ab production (Offe et al. 2006; Spoelgen et al.
2006). Cav-1 may be a negative modulator of sorLA’s
function, hence leading to a scenario like retromer dys-
function, and decreased or knocked-out sorLA levels that
are permissive of enhanced Ab production (Seaman 2004;
Andersen et al. 2005; He et al. 2005). Another intriguing
possibility is that cav-1, and/or an increased cav-1: sorLA
ratio, could facilitate progression of APP along the mul-
tivesicular body–exosomal pathway (Rajendran and
Simons 2009; Rajendran et al. 2006) leading to enhanced
toxic amyloid peptide biogenesis both in neurons and glia.
Indeed, membrane raft markers have been found associated
with the latter pathway (Rajendran et al. 2006, 2007;
Schneider et al. 2008; Rajendran and Simons 2009).
Alternatively,althoughtheintracellular co-localizationof
sorLA and cav-1 may be crucial in determining the amy-
loidogenic potential of glia, the observation of increased
sorLA: cav-1 co-localization at the plasmalemma level in
differentiated C6 cells (Fig. 5) suggests that interaction
between sorLA and cav-1 at the plasmalemma level may
lead to its ‘‘trapping’’ or retention and inhibition of its
internalization, a necessary step for its anti-amyloidogenic
action. An increased cav-1:sorLA ratio may favor this
interaction and prevent sorLA from internalizing and exert
its APP-retention role in the intracellular (EE and trans-
Golgi) compartments, hence leading to an increased amy-
loidogenic potential in glia. Therefore, our ﬁndings strongly
support the view that the glial compartment is an important
contributor to the role of sorLA and cav-1 in AD and neu-
rodegeneration. These ﬁndings may apply to the neuronal
compartment, since cav-1 may be expressed in neurons, or
raft proteins such as ﬂotillins may exert a similar effect.
The ﬁndings presented highlight the value of the glial
models systems for the study of sorLA’s expression and
subcellular trafﬁcking. The dynamics unveiled could apply
to neurons and non-neuronal cells. These ﬁndings also bear
physiological and pathophysiological relevance leading us
to acknowledge the need to consider the glial cell raft
microdomains and the raft-associated protein cav-1 in our
schemes on the trafﬁcking of sorLA and its role in the
processing of APP in AD. For instance, genetic variants of
sorLA may need to consider cav-1 levels and mutations in
AD diagnosis and treatment. It may be possible that certain
cav-1 mutants or decreased cav-1 levels may offer a
‘‘neuroprotective advantage’’ to persons expressing sorLA
mutants or decreased sorLA levels. Hence, control of glial
activation could focus on the control of the cav-1:sorLA
ratio as a strategy for the modulation of AD progression, or
in alterations in the trafﬁcking behavior of sorLA, since its
retention (trapping) at the level of the plasmalemma or in
discrete endosomal compartments by cav-1 may prevent it
form exerting its anti-amyloidogenic action.
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